GnRH blockers: a changing paradigm in the management of prostate cancer

The development of GnRH blockers provides a new class of hormonal agent with a different, direct mode of action. Degarelix, a newly approved GnRH blocker, has displayed a fast, profound and sustained suppression of testosterone and prostate-specific antigen levels without subsequent tumour flare effects. This paper considers the current evidence for this new treatment approach and how this may impact on current urology nursing practice.